3apc | pdb_00003apc
From Proteopedia
Crystal structure of human PI3K-gamma in complex with CH5132799
| ||||||||||||
Structural highlights
Publication Abstract from PubMedPhosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer. Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton. Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety. CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3Kalpha (IC(50)=0.014muM). In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity. CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.,Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida M, Kondoh O, Kuramoto S, Ogawa K, Aoki Y, Shimma N Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. Epub 2011 Jan 22. PMID:21316229[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||||||||
This page was last modified 09:32, 5 November 2014.